Researchers evaluated the efficacy and safety of ixekizumab over a 16-week period for the treatment of juvenile psoriatic arthritis or enthesitis-related arthritis.

Researchers assessed the safety and efficacy of apremilast over a 48-week period for the treatment of early oligoarticular psoriatic arthritis.

In three different trials, the sex differences were mapped between women and men with psoriatic arthritis in their manifestations and outcomes.

Dr Philip J. Mease shares his insights on the use of ultrasound in psoriatic arthritis diagnosis, particularly in uncovering ...

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

Guidance particularly addresses the value of ultrasound in patient-provider shared decision-making in management of care.

“Spondyloarthritis” is an umbrella term for inflammatory conditions that cause arthritis. Examples include ankylosing spondylitis and psoriatic arthritis. Spondyloarthritis is a group of ...

Biologics are a class of drugs used to treat various diseases to help improve outcomes. Understanding the options can help you work with your doctor to make informed treatment decisions. Most of ...

myCME is the premier destination for continuing medical education (CME) and continuing education (CE), committed to providing high-quality, evidence-based, and user-friendly courses tailored to the ...